Drug treatments in development for Alzheimer’s disease

Abstract

Approaching 30 years aer initial descriptions of the therapeutic benets of tacrine (Summers et al., 1986), we still only have symptomatic therapies for Alzheimer’s disease (AD) and no therapies for the other dementias. Only four drugs are regularly used for AD (donepezil, galantamine, rivastigmine and memantine) and no new drug has been marketed for almost 20 years. Disease-modifying therapies for dementia are desperately needed.